Product Description
ABBV-722 is a lysophosphatidic acid receptor 1 (LPAR1) antagonist antibody being investigated for the treatment of systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF). LPAR1 contributes to the underlying pathology of fibrotic diseases and amplifies inflammation and fibrosis in the lungs, among other tissues. Inhibition of LPAR1 may address SSc and IPF pathogenesis. (Sourced from: https://www.abbvie.com/science/pipeline.html)
Mechanisms of Action: LPAR1 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07567781 |
M25-744 | P1 |
Recruiting |
Healthy Volunteers |
2026-07-01 |
88% |
2026-05-06 |
Primary Endpoints|Treatments |
NCT07425899 |
M25-431 | P1 |
Recruiting |
Healthy Volunteers |
2026-08-01 |
88% |
2026-04-01 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT07599761 |
M25-294 | P1 |
Recruiting |
Healthy Volunteers |
2026-07-01 |
88% |
2026-05-21 |
Primary Endpoints|Treatments |
NCT07502417 |
M26-248 | P1 |
Recruiting |
Healthy Volunteers |
2026-07-01 |
88% |
2026-04-01 |
Primary Endpoints |
NCT06673238 |
M25-150 | P1 |
Recruiting |
Healthy Volunteers |
2026-04-01 |
50% |
2025-07-22 |
|
NCT07361367 |
M25-432 | P1 |
Completed |
Healthy Volunteers |
2026-03-23 |
88% |
2026-04-28 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|